Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal (groups A, C, Y and W135) polysaccharide conjugate vaccine
- Development stage
- Unknown
- Lead developer
- Beijing Minhai Biological
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
MCV-ACYW135 is a quadrivalent meningococcal conjugate vaccine developed by Beijing Minhai Biotechnology for the prevention of invasive meningococcal disease caused by *Neisseria meningitidis* serogroups A, C, Y, and W135. The vaccine is composed of capsular polysaccharides from these four serogroups, each chemically conjugated to a carrier protein. This conjugation converts the polysaccharide antigens into T-cell dependent antigens, thereby enhancing immunogenicity and inducing immunological memory, which is particularly critical for protection in infants and young children. A Phase 3 clinical trial (NCT02003495) conducted in China evaluated the safety and immunogenicity of the vaccine in healthy children aged 2 months to 6 years, demonstrating its potential to provide broad protection against the most common serogroups associated with meningococcal meningitis.
- Other names
- quadrivalent meningococcal conjugate vaccineMinhai MCV-ACYW135MCV-ACYW135 vaccineMCV-ACYW-135 vaccineMCV-ACYW 135 vaccine
02
Targets
BCR (Immunoglobulin G B Cell Receptor)CD4 (T lymphocyte surface antigen)NmA CPS (Neisseria meningitidis group A capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharideMenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)
Beyond the preview
Go deeper on meningococcal (groups A, C, Y and W135) polysaccharide conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal (groups A, C, Y and W135) polysaccharide conjugate vaccine.